The Role of 20-HETE in the Pathogenesis of Dementia
20-HETE 在痴呆发病机制中的作用
基本信息
- 批准号:10192612
- 负责人:
- 金额:$ 3.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgingAlbuminsAlkane 1-monooxygenaseAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAnimal ModelAtherosclerosis Risk in CommunitiesAttenuatedBlood - brain barrier anatomyBlood PressureBlood capillariesBrainCYP4A1 geneCaliberCell CountCellsCerebrovascular CirculationCerebrovascular DisordersChromosome 5ChronicCognitionConsomic StrainDahl Hypertensive RatsDementiaDevelopmentElderlyEnzymesEssential HypertensionEvans blue stainExhibitsExtravasationGPR75 geneGenesGeneticGenetic Predisposition to DiseaseHippocampus (Brain)HistologyHomeostasisHydroxyeicosatetraenoic AcidsHypertensionImmunohistochemistryImpaired cognitionImpairmentKnock-inLeadLinkModelingMonitorMutationNerve DegenerationNervous System TraumaNeurocognitivePathogenesisPathway interactionsPatientsPerfusionProductionProteinsRattusRattus norvegicusReportingRiskRisk FactorsRoleStrokeStructureTestingTransgenic OrganismsVariantVascular Cognitive ImpairmentWestern BlottingWorkarmbehavior testcell typecerebral arterycerebral capillarycerebral hemodynamicscognitive developmentcognitive functiondensitydiabeticgenetic testinginhibitor/antagonistliquid chromatography mass spectrometryloss of functionmotor deficitnovelolder patientpressurereceptorresponsesalt sensitivewater maze
项目摘要
Aging and hypertension are primary risk factors for the development of cerebral vascular disease (CVD), stroke,
vascular cognitive impairment (VCI), and Alzheimer’s disease (AD). However, the genes and pathways
determining genetic susceptibility are unknown. In preliminary studies, Dr. Roman’s lab identified sequence
variants in t h e CYP4A11 and 4F2 genes, which inhibit the formation of 20-HETE, are associated with loss of
hippocampal and AD signature region volumes, and cognitive dysfunction in 4,286 elderly patients in the
Atherosclerosis Risk in Communities-Neurocognitive Study (ARIC-NCS). These same variants have been
previously linked to hypertension and stroke, but their contribution to the loss of cognition with aging is novel.
Little is known about the cells that produce 20-HETE or express its newly discovered GPR75 receptor in the
brain or the influence of aging and hypertension on the expression of this pathway. 20-HETE inhibitors have
been reported to attenuate the myogenic response of cerebral arteries and autoregulation of cerebral blood flow
(CBF). Autoregulation of CBF protects the brain from increases in capillary pressure, blood-brain barrier (BBB)
leakage, and neurological damage following elevations in blood pressure. Autoregulation of CBF to elevations
in pressure is often impaired in elderly, hypertensive, diabetic and AD patients, but its role in the development of
cognitive impairment remains to be determined. To validate the association between CYP4A/F mutations and
dementia, and to determine the mechanisms involved, Dr Roman’s group identified a homologous genetic
deficiency in the formation of 20-HETE in Dahl salt-sensitive (SS) rats, and confirmed they exhibit impaired
autoregulation of CBF. They also created transgenic rescue models on the SS genetic background. This project
will now test the hypothesis that a genetic deficiency in the formation of 20-HETE, which impairs CBF
autoregulation, increases pressure to cerebral capillaries to promote BBB leakage, neurodegeneration, and
cognitive dysfunction with aging and/or hypertension. We will identify the cellular localization of the enzymes that
produce 20-HETE and its receptors in the brain, and determine if knock-in of the wild-type Cyp4A1 gene in young
and elderly SS rats restores the production of 20-HETE and protects against the development of cognitive
impairment with aging and/or hypertension. This work has exceedingly high translational value and should lead
to the development of genetic tests to identify patients with CYP4A11 and 4F2 mutations that may be at risk for
the development of cognitive impairment.
衰老和高血压是发展脑血管疾病(CVD),中风,
血管认知障碍(VCI)和阿尔茨海默氏病(AD)。但是,基因和途径
确定遗传易感性是未知的。在初步研究中,罗曼博士的实验室确定了序列
抑制20-HETE形成的T H E CYP4A11和4F2基因中的变体与丧失
海马和AD签名区域量以及4,286名患者的认知功能障碍
社区神经认知研究(ARIC-NCS)的动脉粥样硬化风险。这些变体已经
以前与高血压和中风有关,但是它们对衰老认知丧失的贡献是新颖的。
关于产生20-Hete或表达其新发现的GPR75受体的细胞知之甚少
大脑或衰老和高血压对该途径表达的影响。 20-Hete抑制剂具有
据报道会减弱脑动脉的肌源性反应和脑血流的自动调节
(CBF)。 CBF的自动调节可保护大脑免受毛细管压力,血脑屏障(BBB)的增加
血压升高后泄漏和神经损害。 CBF至海拔的自动调节
在老式,高血压,糖尿病和AD患者中,压力通常会受到损害,但其在发展中的作用
认知障碍仍有待确定。验证CYP4A/F突变与
痴呆症,并确定涉及的机制,罗曼博士的小组确定了同源的通用
Dahl盐敏感(SS)大鼠的20-HETE形成不足,并确认它们暴露于障碍
CBF自动调节。他们还在SS遗传背景上创建了转基因救援模型。这个项目
现在将检验以下假设:在20-HETE的形成中遗传缺乏症会损害CBF
自动调节,增加脑毛细管的压力,以促进BBB泄漏,神经变性和
衰老和/或高血压的认知功能障碍。我们将确定酶的细胞定位
在大脑中产生20-HETE及其接收器,并确定Young中野生型CYP4A1基因是否敲入
SS大鼠较早地恢复了20-HETE的产生,并防止了认知的发展
衰老和/或高血压的损害。这项工作具有极高的翻译价值,应该领导
开发基因检测,以识别患有CYP4A11和4F2突变的患者
认知障碍的发展。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vascular contributions to cognitive impairment and dementia: the emerging role of 20-HETE.
- DOI:10.1042/cs20201033
- 发表时间:2021-08-13
- 期刊:
- 影响因子:0
- 作者:Gonzalez-Fernandez E;Liu Y;Auchus AP;Fan F;Roman RJ
- 通讯作者:Roman RJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ezekiel Gonzalez-Fernandez其他文献
Ezekiel Gonzalez-Fernandez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ezekiel Gonzalez-Fernandez', 18)}}的其他基金
The Role of 20-HETE in the Pathogenesis of Dementia
20-HETE 在痴呆发病机制中的作用
- 批准号:
9906421 - 财政年份:2020
- 资助金额:
$ 3.97万 - 项目类别:
相似国自然基金
温度作用下CA砂浆非线性老化蠕变性能的多尺度研究
- 批准号:12302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于波动法的叠层橡胶隔震支座老化损伤原位检测及精确评估方法研究
- 批准号:52308322
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
微纳核壳结构填充体系构建及其对聚乳酸阻燃、抗老化、降解和循环的作用机制
- 批准号:52373051
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
东北黑土中农膜源微塑料冻融老化特征及其毒性效应
- 批准号:42377282
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
高层建筑外墙保温材料环境暴露自然老化后飞火点燃机理及模型研究
- 批准号:52376132
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and Reversibility
肝硬化患者肾脏健康的新型生物标志物对急性肾损伤发生风险和可逆性的分层
- 批准号:
10675684 - 财政年份:2022
- 资助金额:
$ 3.97万 - 项目类别:
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and Reversibility
肝硬化患者肾脏健康的新型生物标志物对急性肾损伤发生风险和可逆性的分层
- 批准号:
10525756 - 财政年份:2022
- 资助金额:
$ 3.97万 - 项目类别:
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
- 批准号:
10430705 - 财政年份:2022
- 资助金额:
$ 3.97万 - 项目类别:
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
NAD 增强治疗糖尿病肾病:一项随机对照试验
- 批准号:
10668324 - 财政年份:2022
- 资助金额:
$ 3.97万 - 项目类别:
Acute phase protein and cachexia on adaptive immunity in thoracic malignancy
急性期蛋白和恶病质对胸部恶性肿瘤适应性免疫的影响
- 批准号:
21K15584 - 财政年份:2021
- 资助金额:
$ 3.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists